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Abstract
Introduction: In resource-poor areas, infectious diseases may be important causes of morbidity among individuals infected
with the Human T-Lymphotropic Virus type 1 (HTLV-1). We report the clinical associations of HTLV-1 infection among
socially disadvantaged Indigenous adults in central Australia.
Methodology and Principal Findings: HTLV-1 serological results for Indigenous adults admitted 1st January 2000 to 31st
December 2010 were obtained from the Alice Springs Hospital pathology database. Infections, comorbid conditions and
HTLV-1 related diseases were identified using ICD-10 AM discharge morbidity codes. Relevant pathology and imaging
results were reviewed. Disease associations, admission rates and risk factors for death were compared according to HTLV-1
serostatus. HTLV-1 western blots were positive for 531 (33.3%) of 1595 Indigenous adults tested. Clinical associations of
HTLV-1 infection included bronchiectasis (adjusted Risk Ratio, 1.35; 95% CI, 1.14–1.60), blood stream infections (BSI) with
enteric organisms (aRR, 1.36; 95% CI, 1.05–1.77) and admission with strongyloidiasis (aRR 1.38; 95% CI, 1.16–1.64). After
adjusting for covariates, HTLV-1 infection remained associated with increased numbers of BSI episodes (adjusted negative
binomial regression, coefficient, 0.21; 95% CI, 0.02–0.41) and increased admission numbers with strongyloidiasis (coefficient,
0.563; 95% CI, 0.17–0.95) and respiratory conditions including asthma (coefficient, 0.99; 95% CI, 0.27–1.7), lower respiratory
tract infections (coefficient, 0.19; 95% CI, 0.04–0.34) and bronchiectasis (coefficient, 0.60; 95% CI, 0.02–1.18). Two patients
were admitted with adult T-cell Leukemia/Lymphoma, four with probable HTLV-1 associated myelopathy and another with
infective dermatitis. Independent predictors of mortality included BSI with enteric organisms (aRR 1.78; 95% CI, 1.15–2.74)
and bronchiectasis (aRR 2.07; 95% CI, 1.45–2.98).
Conclusion: HTLV-1 infection contributes to morbidity among socially disadvantaged Indigenous adults in central Australia.
This is largely due to an increased risk of other infections and respiratory disease. The spectrum of HTLV-1 related diseases
may vary according to the social circumstances of the affected population.
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Introduction
The Human T Lymphotropic Virus type 1 (HTLV-1) is an
oncogenic retrovirus that preferentially infects CD4+ T cells [1].
Worldwide, HTLV-1 infects at least 5–10 million people who
predominantly dwell in areas of high endemicity in southern
Japan, the Caribbean basin, parts of South America and inter-
tropical Africa. A smaller endemic focus is present in central
Australia [2] and we have recently shown this to be due to
infection with the HTLV-1c subtype [3]. Epidemiological and
clinical associations have been best described for populations in
the Caribbean basin, South America and Japan [1]. A minority of
HTLV-1 carriers experience clinically significant sequelae,
including a rapidly progressive hematological malignancy, Adult
T cell Leukemia/Lymphoma (ATLL) [4,5], and inflammatory
disorders, such as HTLV-1 associated myelopathy/tropical spastic
paraparesis (HAM/TSP) [6]. A severe exudative eczema, infective
dermatitis, predominantly affects children [7]. In Japan and the
Caribbean, life-time risks range between 0.3–4% for HAM/TSP,
1–5% for ATL [1] and approach 10% for HTLV-1 associated
malignancy or inflammatory diseases overall [1].
Infectious diseases also contribute to HTLV-1 related morbidity
and mortality. Severe scabies [8], mycobacterial infections [9] and
symptomatic infection with the nematode parasite Strongyloides
stercoralis [10,11] are all more frequent among HTLV-1 carriers. In
areas endemic for HTLV-1 and S.stercoralis, HTLV-1 infection is
the major risk factor for complicated strongyloidiasis or ‘hyper-
infection’, which is associated with pulmonary involvement [12]
and life-threatening sepsis due to enteric bacterial pathogens [13].
Infection with S.stercoralis may also reduce the latent period
PLOS Neglected Tropical Diseases | www.plosntds.org 1 January 2014 | Volume 8 | Issue 1 | e2643
required for the development of ATLL [14]. HTLV-1 infection
reduces clearance rates of hepatitis C virus and increases the risk of
liver disease and liver disease-related deaths [15]. Whether the risk
of chronic hepatitis B virus (HBV) infection is similarly affected is
unknown. Interactions between HTLV-1 related inflammatory
diseases and infection have also been demonstrated. Infective
dermatitis, for example, typically affects HTLV-1 carriers from
lower socio-economic backgrounds and predisposes to skin
infections with bacterial pathogens [7], which may progress to
life-threatening invasive disease [16]. Recently, we reported high
rates of HTLV-1 infection among socially disadvantaged Indig-
enous adults with bronchiectasis in central Australia [17].
Clinically significant pulmonary disease is not a feature of HTLV-1
infection in other developed countries [18–20], and we suggested that
recurrent lower respiratory tract infections (LRTI) might contribute
to this risk in our study population. The spectrum of HTLV-1
related clinical diseases may therefore differ according to social
status and the risk of environmental exposure to other pathogens.
However, demonstrating such an effect requires diagnostic capa-
bilities that may not be available in developing countries in which a
heavy burden of infectious diseases affects a population with a high
prevalence of HTLV-1 infection.
Central Australia is well placed to study the associations
between poverty and infectious diseases [21]. HTLV-1 is endemic
to this region and infects 7.2–13.9% [22,23] of socially disadvan-
taged Indigenous adults. There has been no attempt to control
HTLV-1 transmission among the Indigenous residents of central
Australia, most of whom reside in isolated remote communities in
conditions of considerable socio-economic disadvantage [21].
Those who live in the major regional center of Alice Springs
dwell in either overcrowded ‘town camps’, which have poor
amenities and limited refuse disposal, or are integrated with the
majority of the non-Indigenous population within the township’s
suburbs [21]. Central Australia also has the highest reported blood
stream infection (BSI) incidence rates [21] and the highest prevalence
rate of adult bronchiectasis [17] worldwide. Prevalence rates of
chronic HBV infection exceeded 20% in some communities prior to
the introduction of vaccination [24]. Consequently, infection-
related mortality rates approach those of some African countries
prior to the current HIV pandemic [25]. A single well-resourced
community-based hospital, Alice Springs Hospital (ASH), serves this
region of 1,000,000 km2 (Fig. 1). Critically ill patients are retrieved
by air to tertiary referral centers 1,500 km away. Medical services
are provided without charge and, notwithstanding the poor social
circumstances of the resident population, sophisticated radiological,
microbiological and other diagnostic facilities are readily available.
The present study describes the spectrum of HTLV-1 associated
diseases that affects socially disadvantaged Indigenous adults in
central Australia.
Methods
Ethics statement
This study was approved by the Central Australian Human
Research Ethics Committee, which is a regional committee
supervised by the National Health and Medical Research Council
of Australia.
Data collection
All adults (age $15 years) admitted to ASH between 1st January
2000 and 31st December 2010 who had an HTLV-1 screening test
performed were identified from the hospital pathology data-base.
HTLV-1 testing at ASH is performed where there are clinical
suspicions of HTLV-1 related diseases, including malignancy,
neurological disease, strongyloidiasis and bronchiectasis. Demo-
graphic data including ethnicity, dates of birth and death, indigenous
status and place of residence were obtained for all patients from the
ASH patient management system. For each admission between 1st
January 2005 and 31st December 2010 International Statistical
Classification of Diseases and Related Health Problems, Tenth
Revision, Australian Modification (ICD-10 AM) morbidity codes
relating to non-communicable diseases, possible HTLV-1 related
conditions and infectious diseases were also extracted (Table S1).
Discharge morbidity codes for admissions prior to 2005 were not
available and patients who died prior to this date were therefore
excluded from statistical analysis. All data were de-identified prior
to analysis. Infectious diseases were grouped according to ICD-10
AM codes; i) sepsis or bacterial infection for which a focus was not
stated, ii) specified foci of infection and iii) strongyloidiasis (Table
S1). HTLV-1 related conditions included ATLL, HAM/TSP,
bronchiectasis and infective dermatitis. Cases of ATLL and HAM/
TSP were also sought from specialist neurological and hematolog-
ical units that provide tertiary level care to ASH patients. Case
notes, microbiology, radiology and other relevant pathology results
were reviewed for all patients with possible HTLV-1 related
conditions including ATLL, neurological disorders, bronchiectasis
and infective dermatitis.
Residence
Place of residence was categorized as i) remote (.80 km from
Alice Springs), ii) Alice Springs town camp and iii) urban (resident
in Alice Springs, but not in a town camp). Remote residence was
further divided into quadrants (north, south, east and west) relative
to Alice Springs.
Infections and definitions
Results for S.stercoralis serology, HBV serology and blood
cultures were obtained from the ASH pathology data-base.
During the study period, S.stercoralis serology was performed using
Author Summary
The Human T-Lymphotropic Virus type 1 (HTLV-1) infects
at least 5–10 million people worldwide. In developed
countries, the most frequently reported HTLV-1 associated
diseases include a fatal hematological malignancy, Adult T-
cell Leukemia/Lymphoma (ATLL), and the neurological
disorder, HTLV-1 associated myelopathy (HAM), which
arise in ,10% of HTLV-1 carriers during their lifetime.
However, most HTLV-1 carriers live in resource-poor areas
where infectious diseases, such as strongyloidiasis, could
be more important causes of morbidity. Demonstrating
such an effect is difficult due to the resource constraints
experienced by developing countries in which populations
with a substantial burden of infectious diseases reside in
areas that are highly endemic for HTLV-1. This is not the
case in HTLV-1 endemic central Australia where Indige-
nous Australians have, for example, among the highest
reported blood stream infection rates worldwide in a
setting in which sophisticated medical facilities are readily
available. We report that bronchiectasis, blood stream
infections and admissions with lower respiratory tract
infections and strongyloidiasis are associated with HTLV-1
infection. These conditions were far more common than
HTLV-1 associated malignancies or neurological conditions
in this socially disadvantaged Indigenous population. The
spectrum of HTLV-1 related diseases therefore varies
according to the social circumstances of the affected
population.
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an in-house enzyme-linked immunosorbent assay based on antigen
extracts of Strongyloides ratti, which is highly sensitive and specific. A
blood culture from which a pathogen was isolated defined a ‘BSI
episode’. Repeated culture of the same organism from blood
culture was regarded as a separate ‘episode’ only if blood samples
were drawn more than one month apart. Blood stream infections
excluded potential contaminants including coagulase negative
staphylococci, bacillus spp., coryneforms and viridans streptococci
unless grown from more than one BC in a 24 hour period and
Acinetobacter spp in the absence of an identifiable focus. For
statistical analysis, the major BSI pathogens were grouped
according to their most likely origin: i) skin (Staphylococcus aureus
and Streptococcus pyogenes), ii) respiratory (Streptococcus pneumoniae and
Haemophilus influenzae), iii) urinary tract (Escherichia coli) and iv)
gastrointestinal tract (Enterobacteriaceae other than E.coli).
‘Definite bronchiectasis’ was defined as an ICD-10 AM code for
bronchiectasis that was confirmed by High Resolution Computed
Tomography (HRCT) chest according to American College of
Chest Physicians criteria. ‘Possible bronchiectasis’ was defined as
an ICD-10 AM code for bronchiectasis in the absence of HRCT
chest confirmation of this diagnosis. A diagnosis of ATLL [4] and
HAM/TSP [26] was made using established criteria. Cases of
HAM/TSP were categorized as ‘probable’ if the clinical presen-
tation was consistent with HAM/TSP in the absence of confir-
matory analysis of cerebrospinal fluid (CSF) [26].
HTLV-1 studies
Initial screening tests were performed using the Serodia HTLV-
1 particle agglutination assay (Fujirebio, Japan) or Architect
rHTLV-I/II assay at the Royal Darwin Hospital, Northern
Territory of Australia, (1458) or the Institut Pasteur, Paris (156).
Positive samples were again tested using both the Serodia HTLV-
1 particle agglutination assay and Murex HTLV-I+II test kit
(Murex Diagnostics, Dartford, UK)(National Serological Refer-
ence Laboratory, Melbourne) or an indirect immunofluorescence
assay (IFA) using an HTLV-1-transformed human T cell line
(MT2)(Institut Pasteur). HTLV-1 serostatus was then confirmed
by Western blot (HTLV Blot 2.4, MP Diagnostics) using stringent
criteria for all samples for which screening tests were positive.
Statistics
Categorical variables were summarized using frequency and
percentage and compared using a Chi-square test or, in the case of
small numbers, a Fisher’s Exact test. Multiple simultaneous
comparisons were adjusted for using a Bonferroni correction.
Continuous variables were assessed for significant departures from
normality with normally distributed variables summarized using
mean and standard deviation (SD) and compared using a t-test
whilst skewed variables were summarized using median and inter-
quartile range (IQR) and compared using a Wilcoxon rank-sum
test.
Predictors of HTLV-1 seropositivity were examined using
Poisson regression with robust standard errors. Strongyloides
admissions (identified by ICD-10 AM codes), rather than serology,
were included in the multivariable model because these are more
likely to reflect symptomatic strongyloidiasis [10,11,27]. Direct
modeling of relative risk (RR) using Poisson was preferred over
Odds Ratios (OR) from logistic regression to estimate RR due to
the frequency of the outcome studied. A link test was used to assess
the model for specification error whilst overall goodness of fit was
assessed using both visual examination of residuals coupled with a
likelihood-ratio test and a Pearson goodness-of-fit test.
Incidence rates of admission count by diagnostic group were
expressed as a proportion of the total number of HTLV-1
seropositive and seronegative patients respectively. Predictors of
admission counts for a range of diagnostic groups according to
HTLV-1 seropositivity were examined using negative binomial
regression and are presented with their negative binomial 95%
confidence intervals. Negative binomial modeling was preferred
over straight Poisson regression due to over-dispersion in admission
count outcome variables. The model coefficients represent the
estimated change in admission counts for a particular level of a
predictor variable. The influence of HTLV-1 seropositivity on
admission count was adjusted for demography and comorbidities.
In the case of admissions with asthma, LRTI, pneumonia and
chronic obstructive pulmonary disease, the model was adjusted for
both definite and possible bronchiectasis and tobacco smoking. A
link test was used to assess the model for specification error whilst
overall goodness of fit was assessed using both visual examination of
residuals coupled with a likelihood-ratio test and a Pearson goodness-
of-fit test.
Predictors of hepatitis B surface antigen (HBsAg) positivity were
analysed using logistic regression. In this case, a logistic approach
was preferred secondary to the rarity of the outcome. Overall
model fit was assessed using a Hosmer & Lemeshow goodness-of-
fit test.
Predictors of time to mortality were examined using Cox Propor-
tional Hazards Regression. Analysis of scaled Schoenfeld residuals
were used to assess compliance with the proportional hazards
assumption. For this analysis patients with possible bronchiectasis
were assumed not to have the condition.
All reported p-values are two-tailed and for each analysis p,
0.05 was considered significant. All analyses were conducted using
Stata version 12 (StataCorp, College Station, Texas).
Results
HTLV-1 screening tests were performed for 1614 Indigenous
adults and these were positive for 624 (38.7%) cases. Samples from
605 patients were referred for confirmatory Western blot tests.
These were indeterminate in 73 cases (4.6%) and confirmedHTLV-1
infection for 531 patients (33.3%). Patients whose western blot results
were indeterminate were excluded from further analysis, as were 74
patients (HTLV-1 seropositive, 24; HTLV-1 seronegative, 50) who
died prior to 2005. The subsequent analysis therefore included 1451
Indigenous adults (HTLV-1 seropositive, 507; HTLV-1 seronega-
tive, 944) who were admitted 115,919 times (HTLV-1 seropositive
39,967; HTLV-1 seronegative 75,952) during the study period.
Demographics
HTLV-1 seropositivity rates among males increased significant-
ly with age (,45 years, 106/329 (32.2%); $45 years, 135/319
(42.2%); p= 0.008). Rates were otherwise not significantly different
between age groups or genders (Table 1). Seropositivity rates
differed according to place and type of residence. Rates were lowest
among residents of communities north of Alice Springs (14.6%) and
Figure 1. Map of the study area in central Australia including HTLV-1 seropositivity rates for 952 Indigenous adult residents of
remote communities divided by quadrant according to their residence relative to the regional center of Alice Springs (green circle).
Number of residents tested: North, 335; East, 69; South, 241; West, 307. Abbreviations: NT, Northern Territory of Australia; QLD, Queensland; SA, South
Australia; WA, West Australia. Scale bar = 250 km.
doi:10.1371/journal.pntd.0002643.g001
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highest among those from communities to the south (64.3%) and
west (37.5%)(Fig. 1)(Table 1). Seropositivity rates were higher
among town camp residents (42.6%) and lowest among those living
elsewhere in the township (27.0%). Demographic risk factors for
HTLV-1 infection after multivariable analysis included age
(adjusted RR, 1.01 per year; 95% CI, 1.01–1.02; p= 0.000) and
residence in communities to the south (aRR 3.83; 95% CI, 2.64–
5.57; p= 0.000) and west (aRR 2.77; 95% CI, 1.54–3.37; p=,
0.001) of Alice Springs relative to those in the north (Table 2).
Medical conditions previously associated with HTLV-1
infection
i) Respiratory diseases. A bronchiectasis-related discharge
morbidity code was recorded for 170 patients. Bronchiectasis was
confirmed radiologically in 142 patients of whom 81 (57.0%) were
HTLV-1 seropositive. Radiologically confirmed bronchiectasis was
an independent predictor of HTLV-1 infection in a multivariable
model (aRR 1.35; 95%CI, 1.14–1.60; p= 0.001) (Table 2). HTLV-
1 carriers were also more likely to be admitted with LRTI other
than pneumonia, pneumonia and bronchiectasis (Table 3) and had
higher admission numbers for asthma, LRTI other than pneumo-
nia, pneumonia and bronchiectasis (Table 4). These associations
remained after adjusting for demographic factors and comorbidities
(Table 5).
ii) Strongyloidiasis. Strongyloides serology was performed
for 1126 (77.6%) patients of whom 269 (23.9%) were Strongyloi-
des seropositive (Table 6). Although HTLV-1 carriers were more
likely to record a Strongyloides serology result (Table 6), Strongy-
loides seropositivity rates were not significantly higher in this group
(HTLV-1 seropositive, 27.1%; HTLV-1 seronegative, 22.0%
(p= 0.063)(Table 6). Routine stool microscopy was performed in
only 47 cases at the time of diagnosis with strongyloidiasis and stool
was cultured for strongyloides in only eight of these cases. Larvae
were identified in 19 cases (HTLV-1 seronegative, 7; HTLV-1
seropositive, 12). The numbers of admissions with strongyloidiasis
were significantly higher among HTLV-1 carriers (Table 4) and the
likelihood of admission with strongyloidiasis remained increased in a
multivariable model (aRR 1.38; 95% CI, 1.16–1.64; p= 0.000)
(Table 2).
iii) Scabies. HTLV-1 carriers were more likely to record a
discharge morbidity code for scabies (Table 3) and had higher
admission rates for this condition (Table 4); however, this
association was lost in an adjusted model (Table 5). Severity of
scabies could not be determined from ICD-10 AM codes and skin
scrapings were performed for few patients.
iv) Malignancy, HAM/TSP and infective dermatitis. The
risk of non-hematological malignancies was significantly reduced
among HTLV-1 carriers (Table 2). Six patients were admitted
with hematological malignancies including two who were diag-
nosed with ATLL after referral to a tertiary hospital. The clinical
presentation of four HTLV-1 seropositive patients was consistent
with HAM/TSP; however, in no case were HTLV-1 specific
investigations applied to CSF. A single patient with HTLV-1
related infective dermatitis was identified.
Table 1. Patient characteristics for 1451 Indigenous Adults admitted 2005–2010a.
HTLV-1 WB result
Level Positive (n =507) Negative (n =944) p-value
Sex n (% of level) Male/Female 241 (45.4)/266 (50.1) 407 (41.0)/537 (54.0) 0.106
Age at test, median years (IQR) 47.1 (38.7, 57.4) 43.5 (32.9,55.3) ,0.001
Age
,45 years Male/Female 106 (32.2)/116 (29.9) 223 (67.7)/272 (70.1) 0.503b
$45 years Male/Female 135 (42.2)/149 (36.1) 184 (57.8)/264 (63.9) 0.086b
Residencec, n (% of level)
Town Camp 107 (42.6) 144 (57.4) 0.001g
Remote 308 (38.5) 493 (61.6)
Nursing Home 18 (34.6) 34 (65.4)
Urban 57 (27.0) 154 (73.0)
Quadrantd, n (% of level)
North (n = 335) 49 (14.6) 286 (85.4) ,0.001f
East (n = 69) 12 (17.4) 57 (82.6)
South (n = 241) 155 (64.3) 86 (35.7)
West (n = 307) 115 (37.5) 192 (62.5)
Deathe, n (%) 120 (23.7) 218 (23.1) 0.805
Age at death, median years (IQR) 56.9 (46.2,63.9) 53.2 (44.4,62.5) 0.235
aExcluding patients with an indeterminate western blot and those who died prior to 2005.
bAnalyzed according to gender within each group.
cExcluding 134 patients who resided outside central Australia and 2 patients whose place of residence was unknown. Data are expressed as proportion of total patients
tested for each place of residence.
dResidents of remote communities relative to the regional center of Alice Springs and excluding 498 Alice Springs residents. Data are expressed as proportion of total
patients tested for each quadrant.
eDied during observation period.
fAll pair-wise quadrant comparisons were p,0.001 (Bonferroni-corrected), except the North vs East comparison.
gPair-wise comparisons of urban-residence compared with all other residences were p,0.001 (Bonferroni-corrected).
doi:10.1371/journal.pntd.0002643.t001
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Bacterial infections
Nearly 70% of patients (HTLV-1 seropositive, 391; HTLV-1
seronegative, 621) recorded at least one discharge code for sepsis
with no focus specified during the study period. Although HTLV-
1 carriers more often recorded discharge codes for sepsis with no
focus specified (Table 3) and had higher admission numbers for
this category (Table 4), these associations were lost after adjusting
for covariates (Table 5). HTLV-1 carriers were also more likely to
experience a BSI (Table 6) and had more BSI episodes after
adjusting for covariates (Table 5). When analyzed according to the
most likely origin of infection, BSI from a probable gastrointestinal
source remained significantly associated with HTLV-1 infection in
a multivariable model (aRR, 1.36; 95% CI, 1.05–1.77; p= 0.020)
(Table 2).
Hepatitis B Virus
Among 988 (68.1%) patients tested, 127 (12.9%) were HBsAg
positive of whom 16 (12.6%) were also HBeAg positive (Table 6).
The geographic distribution of HBsAg positivity was similar to that
of HTLV-1 seropositivity. Risk was greatest among residents of
remote communities to the south (unadjusted odds ratio (uOR),
3.98; 95% CI, 2.23–7.10) and west (uOR, 2.23; 95% CI, 1.25–
3.99) compared with northern communities and was reduced for
urban relative to remote residents (uOR, 0.30; 95% CI, 0.14–
0.64). Although HTLV-1 infected patients were more likely to be
HBsAg positive (HTLV-1 seropositive, 65/201 (32.3%); HTLV-1
seronegative, 62/338 (18.3%)(p =,0.001) (Table 6), exposure to
HBV was more frequent among HTLV-1 seropositive patients
(anti-HBc positive: HTLV-1 seropositive, 59.6%; HTLV-1 sero-
negative, 51.9%)(p = 0.021)(Table 6) and HBsAg positivity was not
associated with HTLV-1 infection in a multivariable model
(Table 2).
Mortality
Among 338 deaths that occurred during 5,739 years of follow-
up, 120 (23.7%) were HTLV-1 seropositive and 218 (23.1%) were
HTLV-1 seronegative. There was no difference between HTLV-1
seropositive and seronegative patients in median age of death
(HTLV-1 seropositive, 56.9 years; IQR, 46.2, 63.9); HTLV-1
seronegative, 53.2 years; IQR, 44.4, 62.5) (Table 1). Demographic
risk factors for death included male gender and increasing age
(Table 7).
Bronchiectasis (HR, 2.07; 95% CI, 1.45–2.98; p = 0.000) and
BSI with Enterobacteriaceae other than E.coli (HR 1.78; 95% CI,
1.15–2.74; 0.009) remained significant predictors of death after
multivariable analysis (Table 7). Other risk factors for death were
S.pneumoniae BSI (HR, 1.70; 95% CI, 1.09–2.64; p = 0.018) and
non-communicable diseases (chronic liver disease, diabetes and
malignancy)(Table 7).
Discussion
In a hospitalized cohort of Indigenous Australian adults, we
found an HTLV-1 seropositivity rate (33.3%) that was approxi-
mately three times the estimated background rate in central
Australia (7.2–13.9%) [22,23]. This suggests that HTLV-1
associated morbidity in our study population may substantially
exceed that resulting from the occasional cases of ATLL and
HAM/TSP that are reported here. Consistent with its global
epidemiology [2], HTLV-1 carriers were more likely to live in
poverty in town camps or remote communities and more often
had a history of harmful alcohol consumption. HTLV-1 infection
was associated with strongyloidiasis and blood stream infections
with enteric pathogens; however, respiratory diseases contributed
most to HTLV-1 related morbidity in this socially disadvantaged
Indigenous population. After adjusting for covariates, HTLV-1
infection was associated with bronchiectasis and with increased
admission numbers for all respiratory conditions studied with the
exception of chronic obstructive pulmonary disease.
Pulmonary involvement is common among HTLV-1 carriers
elsewhere. Radiological abnormalities, for example, have been
reported in 50% of Japanese patients with HAM/TSP and 30% of
asymptomatic HTLV-1 carriers who were examined by chest X-
ray [28] and chest CT [29], respectively. Airway involvement is
frequent in this population; chest CT reveals bronchiolitis or
bronchitis in 19% [30] and bronchiectasis in 18–26% [29,30] of
cases. Lymphocyte infiltration of bronchioles [31] and partial
bronchiolar obstruction [31,32] are the histopathological corre-
lates of these radiological findings. Lymphocytes obtained from
HTLV-1 carriers by bronchoalveolar lavage (BAL) have high
HTLV-1 proviral loads [33,34] and these are correlated with those
of peripheral blood [31]. An inflammatory response to the HTLV-1
Table 2. Adjusted Poisson modeling of predictors of HTLV-1
infection.
Relative Risk 95% CI p-value
Age 1.01 1.01–1.02 0.000
Male Gender 1.00 0.88–1.15 0.968
Residence
Type
Remote reference
Town Camp 0.940 0.57–1.55 0.809
Urban 0.711 0.42–1.21 0.211
Remote Areaa
North reference
East 1.34 0.73–2.44 0.347
South 3.83 2.64–5.57 ,0.001
West 2.77 1.54–3.37 ,0.001
Bronchiectasisb 1.35 1.14–1.60 0.001
ICD-10 AM coded conditionsc
Alcohol 1.45 1.25–1.68 0.000
Malignancyd 0.51 0.32–0.83 0.007
Strongyloidese 1.38 1.16–1.64 0.000
Microbiology
BSIf
Enteric 1.36 1.05–1.77 0.020
Skin 1.14 0.94–1.39 0.187
Respiratory 1.19 0.95–1.48 0.128
HBsAg 1.18 0.98–1.42 0.089
aResidence in remote communities relative to the regional center of Alice
Springs.
bPatients for whom an ICD-10 AM discharge morbidity code of bronchiectasis
was recorded and where this was confirmed by HRCT.
cConditions identified from discharge morbidity codes.
dExcluding hematological malignancies.
eStrongyloides identified by ICD-10 AM code.
fBlood stream infections identified from blood cultures. Enteric pathogens,
Enterobacteriaceae other than Escherichia coli; skin pathogens, Staphylococcus
aureas and Streptococcus pyogenes; respiratory pathogens, Streptococcus
pneumoniae and Haemophilus influenzae.
Abbreviations: BSI, blood stream infection; HBsAg, Hepatitis B surface antigen
positive.
doi:10.1371/journal.pntd.0002643.t002
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antigen load derived from infected lymphocytes is thought to be the
major determinant of other HTLV-1 related inflammatory diseases
[35]. Airway inflammation in response to HTLV-1 antigens, such as
the immuno-dominant regulatory protein, Tax [30], may therefore
provide the pathological basis for clinical associations with asthma
and LRTI other than pneumonia in our Indigenous cohort and for
the increased incidence of self-reported asthma among HTLV-1
carriers in the USA [20].
Nevertheless, clinically significant pulmonary disease is an
uncommon feature of HTLV-1 infection in developed countries
[18–20]. In contrast, HTLV-1 infection contributes to bronchiec-
tasis prevalence rates among Indigenous adults in central Australia
that are the highest reported worldwide [17]. In the present study,
142 cases of bronchiectasis were confirmed by HRCT and nearly
60% of these patients were HTLV-1 infected. Consistent with our
previous study [17], bronchiectasis was associated with a very high
early mortality. Previously we have shown that HTLV-1 infection
is associated with more extensive bronchiectasis, more frequent
right heart failure and with bronchiectasis-related deaths [17]. In a
recent case-control study the mean HTLV-1 proviral load in peri-
pheral blood lymphocytes was significantly higher among HTLV-
1 infected patients with bronchiectasis [36]. An HTLV-1 mediated
inflammatory process [35] may therefore underlie HTLV-1 associated
pulmonary disease in our study population. Disease progression to
multifocal bronchiectasis might then follow further pulmonary
injury resulting from recurrent LRTI, which were more common
among HTLV-1 carriers in the present study.
Consistent with the results of other studies [27,37], HTLV-1
carriers in central Australia were not at increased risk of
serologically defined strongyloidiasis. Nevertheless, HTLV-1
infection in other populations is associated with a higher larval
burden and with increased risks of symptomatic, recurrent and
complicated strongyloidiasis [10,11,27]. Our study design and the
use of serological tests to diagnose strongyloidiasis preclude any
Table 3. Comparison of clinical conditions identified by International Classification of Diseases-10 (Australian Modification)
morbidity codes according to HTLV-1 serostatus among 1451 Indigenous adults admitted 2005–2010a.
HTLV-1 Positive (n =507) n (%) HTLV-1 Negative (n =944) n (%) p-value
Non-Communicable Diseases
Smoking 316 (62.3) 538 (57.0) 0.049
Alcohol 275 (54.2) 380 (40.3) ,0.001
Diabetes 252 (49.7) 467 (49.5) 0.932
CKD 164 (32.3) 297 (31.5) 0.730
HD 107 (21.1) 214 (22.7) 0.600
CCF 94 (18.5) 144 (15.3) 0.107
CLD 68 (13.4) 88 (9.3) 0.016
Malignancyb 12 (2.4) 49 (5.2) 0.011
Infections
Sepsis/No focus 391 (77.1) 621 (65.8) ,0.001
Pneumonia 316 (62.3) 477 (50.5) ,0.001
LRTIc 227 (47.2) 342 (40.0) 0.002
Skin 207 (40.8) 349 (37.0) 0.159
Scabies 72 (14.2) 80 (8.5) 0.001
Bone/Joint 51 (10.1) 92 (9.8) 0.849
Respiratory Diseases
Bronchiectasisd 81 (16.8) 61 (7.1) ,0.001
COPD 78 (15.4) 82 (8.7) ,0.001
Asthma 34 (7.1) 54 (6.3) 0.46
HTLV-1 associated conditions
Strongyloides stercoralise 111 (23.1) 157 (18.3) 0.039
HAM/TSPf 4 (0.8) 0 **
ATLL 2 (0.4) 0 **
Infective dermatitis 1 (0.2) 0 **
Data derived from 115,919 admissions (HTLV-1 seropositive 39,967; HTLV-1 seronegative, 75,952) among 481 HTLV-1 seropositive and 856 HTLV-1 seronegative
Indigenous adults.
aExcluding patients with an indeterminate western blot and those who died prior to 2005.
bNon-hematological malignancies.
cLRTI other than pneumonia.
dBronchiectasis confirmed by chest high resolution computed tomography.
eIdentified by ICD-10 AM coding.
fProbable HAM/TSP. Confirmatory tests not applied to cerebrospinal fluid.
**no p-value provided due to small numbers recorded.
Abbreviations: ATLL, adult T cell leukemia/lymphoma; CCF, congestive cardiac failure; CKD, chronic kidney disease; CLD, chronic liver disease; HAM/TSP, HTLV-1
associated myelopathy/tropical spastic paraparesis; HD, hemodialysis; LRTI, lower respiratory tract infection; WB, Western blot.
doi:10.1371/journal.pntd.0002643.t003
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assessment of disease severity. However, HTLV-1 carriers in the
present study were more likely to be admitted with a diagnosis of
strongyloidiasis and had higher admission numbers for this
condition, findings that could result from a higher larval burden.
Unfortunately, our analysis of admission numbers for strongyloi-
diasis might also be confounded by the acknowledged disease
association with HTLV-1 infection, which may lower the clinical
threshold for administering antihelminthics to HTLV-1 carriers
and increase the likelihood that a Strongyloides-related ICD-10
AM code is recorded. The association between HTLV-1 infection
and strongyloidiasis in central Australia therefore requires
confirmation in a prospective study. Nevertheless, high rates of
S.stercoralis infection were found among Indigenous adults in an
arid region of Australia that would appear otherwise hostile to soil
transmitted helminths. The presence of HTLV-1 infected ‘core
transmitters’ who carry a high larval burden may be central to the
survival of S.stercoralis in this environment and could increase the
risk of S.stercoralis infection among other community members.
Strongyloidiasis may also contribute to the very high BSI
incidence rates that have been reported in central Australia [38].
Among Indigenous adults in this region, enteric gram-negative
bacilli are the most common pathogens isolated from blood [38]
and we have previously reported BSI-related deaths among
patients with complicated strongyloidiasis [13].
In our Indigenous Australian cohort, respiratory and infection-
related morbidity were increased among HTLV-1 carriers in the
absence of an increased risk of death. However, an effect of
HTLV-1 infection on mortality may be obscured by analysis
according to HTLV-1 serological status rather than HTLV-1
proviral load, which is closely associated with HTLV-1 related
diseases [1]. Certainly, the recent finding of higher HTLV-1
proviral loads among HTLV-1 carriers with bronchiectasis [36]
suggests that stratifying mortality by HTLV-1 proviral load may
more accurately reflect risk in our patient population. Interesting-
ly, an increased risk of death among HTLV-1 carriers in Guinea-
Bissau [39,40] is associated with higher HTLV-1 proviral loads
Table 4. Admission rates for respiratory conditions and other infections according to HTLV-1 serostatus.
Category HTLV-1 positive (n =490) HTLV-1 negative (n=827) p-value
(admissions/patient) (admissions/patient)
Respiratory Diseasesa
Asthma 0.67 0.19 ,0.0001
LRTIb 1.33 0.86 ,0.0001
Pneumonia 2.05 1.32 ,0.0001
Bronchiectasis 1.95 0.87 ,0.0001
COPD 0.48 0.43 0.1872
Infectionsc
Sepsis 3.98 3.07 ,0.0001
BSI episodesd 0.58 0.42 0.0001
Strongyloides 0.23 0.11 ,0.0001
Scabies 0.19 0.14 0.0385
Admission rates for 1317 adult Indigenous residents of central Australia 2005–2010 admitted to Alice Springs Hospital with respiratory conditions and infections.
Excluding patients who died prior to 2005 and those residing outside central Australia for whom admission data was incomplete.
aIdentified by ICD-10 AM code. Bronchiectasis was confirmed by chest high resolution computed tomography.
bLRTI other than pneumonia.
cIdentified by ICD-10 AM coding with the exception of BSI episodes.
dThe number of blood cultures that yielded a significant pathogen as defined in methods.
Abbreviations: BSI, blood stream infection; COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection.
doi:10.1371/journal.pntd.0002643.t004
Table 5. Adjusted negative binomial regression of predictors
for number of admissionsa with respiratory conditions and
other infections according to HTLV-1 serostatus.
Category Coefficientb 95% CI p-value
Respiratory Diseasesc
Asthma 0.986 0.271, 1.701 0.007
LRTId 0.254 0.067, 0.441 0.008
Pneumonia 0.189 0.039, 0.340 0.014
Bronchiectasis 0.598 0.015, 1.180 0.044
COPD 0.214 20.257, 0.685 0.374
Infectionse
Sepsis 0.123 20.017, 0.264 0.085
BSI episodesf 0.210 0.016, 0.405 0.034
Strongyloides 0.563 0.174, 0.953 0.005
Scabies 0.358 20.011, 0.726 0.057
Adjusted negative binomial modeling of predictors for admission to Alice
Springs Hospital among 1317 adult Indigenous residents of central Australia,
2005–2010. Excluding patients who died prior to 2005 and those residing
outside central Australia for whom admission data was incomplete.
aAdjusted for comorbidities (harmful alcohol consumption, diabetes, chronic
liver disease, chronic kidney disease, hemodialysis), age, gender and place of
residence. Respiratory conditions were also adjusted for smoking and, in the
case of asthma, LRTI and pneumonia, for definite or possible bronchiectasis.
bThe coefficient represents the average change in the number of admissions
that is associated with the presence of the predictor variable according to
HTLV-1 serostatus.
cIdentified by ICD-10 AM code. Bronchiectasis was confirmed by high resolution
computed tomography chest.
dLRTI other than pneumonia.
eIdentified by ICD-10 AM code with the exception of BSI episodes.
fThe number of blood cultures that yielded a significant pathogen as defined in
methods.
Abbreviations: BSI, blood stream infection; COPD, chronic obstructive
pulmonary disease; LRTI, lower respiratory tract infection.
doi:10.1371/journal.pntd.0002643.t005
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Table 6. Results of microbiological tests for 1451 Indigenous Adults admitted 2005–2010a.
HTLV-1 WB result
Positive (n=507) n (%) Negative (n=944) n (%) p-value
Blood Stream Infections 181 (35.7) 254 (26.9) ,0.001
Strongyloides serology
Tested 409 (80.7) 717 (76.0) 0.040
Positive 111 (27.1) 158 (22.0) 0.063a
Borderline 61 (14.9) 115 (16.0)
Negative 237 (58.0) 444 (61.9)
Hepatitis B Virus serology
Tested 337 (66.5) 651 (69.0) 0.290
Anti-HBc 201 (59.6) 338 (51.9) 0.021
HBsAg 65 (32.3) 62 (18.3) ,0.001
HBeAg 5 (7.7) 11 (17.7) 0.077
aPair-wise comparisons of Strongyloides serological results were Bonferroni-corrected.
Abbreviations: HBV, hepatitis B virus; anti-HBc, hepatitis B core antibody positive; HBeAg, hepatitis B e antigen positive; HBsAg, hepatitis B surface antigen positive; WB,
Western blot.
doi:10.1371/journal.pntd.0002643.t006
Table 7. Adjusted Cox proportional hazards modeling of predictors of deatha.
Hazard Ratio 95% Confidence Interval p-value
Ageb 1.03 1.02–1.04 0.000
Male Gender 1.34 1.07–1.68 0.011
Residencec
Type
Remote Reference
Town Camp 1.11 0.82–1.51 0.506
Urban 1.03 0.58–1.83 0.914
Comorbiditiesd
Bronchiectasise 2.07 1.45–2.98 0.000
Diabetes 1.45 1.08–1.95 0.013
Chronic Liver Disease 1.91 1.43–2.56 0.000
Chronic Kidney Disease 1.19 0.88–1.62 0.264
Malignancy 1.81 1.21–2.69 0.004
Cardiac Failure 1.29 0.98–1.69 0.070
Infection
HTLV-1 0.80 0.62–1.03 0.085
Strongyloidesf 1.11 0.96–1.28 0.169
Blood Stream Infectionsg
Enterobacteriaceaeh 1.78 1.15–2.74 0.009
Klebsiella pneumoniae 1.06 0.57–1.96 0.849
Staphylococcus aureus 0.77 0.28–2.14 0.620
Streptococcus pneumoniae 1.70 1.09–2.64 0.018
HBsAg positive 1.10 0.76–1.61 0.605
aIncluding 338 deaths that occurred after 1st January 2005.
bRisk of death for each 5 years increase in age.
cExcluding 134 patients who resided outside central Australia and 2 patients whose place of residence was unknown.
dIdentified by ICD-10 AM coding.
eDefinite bronchiectasis identified by ICD-10 AM code and confirmed by High Resolution Computed Tomography.
fStrongyloides identified by ICD-10 AM code.
gBlood stream infections identified from blood cultures.
hExcluding Escherichia coli.
Abbreviations: HBsAg, hepatitis B surface antigen; HTLV-1, Human T-Lymphotropic Virus type 1.
doi:10.1371/journal.pntd.0002643.t007
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[41]. A modest increase in all-cause mortality has also been
reported among HTLV-1 carriers in Japan [42]; however, no such
association has been found for blood donors in the USA [43].
These geographic differences in HTLV-1 associated mortality
might reflect environmental conditions in resource poor areas that
predispose to recurrent respiratory tract infections and expose
HTLV-1 carriers to other pathogens, such as Mycobacterium
tuberculosis [39] and S.stercoralis [12].
The retrospective nature of this study results in a number of
limitations. First, patients with HTLV-1 related diseases were
identified from discharge morbidity codes. Attempts were made to
identify other patients with these conditions by contacting
specialist medical units to which such patients are referred;
however, cases may have been missed if these were not coded or
referred appropriately. Consequently, our data are likely to under-
estimate the actual burden of HTLV-1 related diseases in this
population. The risk of bronchiectasis attributable to HTLV-1
infection is also likely to be underestimated because individuals
who had not received radiological confirmation of this diagnosis
were assumed not to have the condition. Similarly, the effect of
HTLV-1 infection on respiratory conditions may be underesti-
mated because ‘possible’ bronchiectasis was included in the final
model to account for the increased risk of respiratory infection
resulting from structural lung disease. Determining the strength of
other possible associations was dependent on the accuracy of
discharge coding; however, with the possible exception of strong-
yloidiasis noted above, this is unlikely to vary according to HTLV-
1 serological status. Finally, we assumed that HTLV-1 infection
was acquired in most cases prior to the period in which ICD-10
AM codes were collected. The low annual incidence rate of
HTLV-1 seroconversion among discordant couples [1] suggests
that this is likely to be the case. Indeed, vertical transmission may
be relatively more important in our study population due to the
substantial risks posed by the custom of prolonged breast-feeding
[44]. Strengths of the study are the large sample size, which
included 10% of the region’s Indigenous adult resident population,
the presence of a single well-resourced hospital that serves this
population and the use of data from different sources to study the
HTLV-1 related associations reported here.
In a setting of overcrowded housing, inadequate health hard-
ware and poor community hygiene [45,46], HTLV-1 infection
substantially increases respiratory and infection-related morbidity.
Socially disadvantaged HTLV-1 carriers in our Indigenous
Australian cohort experienced more BSI episodes and were more
often admitted with respiratory conditions including LRTI and
bronchiectasis, which was the major independent risk factor for
death. In contrast to other developed countries [1], infection-
related complications were more common than either ATLL or
HAM/TSP. The spectrum of HTLV-1 related diseases is
therefore likely to vary according to the social circumstances of
the affected population. These findings have not been reported
previously; however, access to the medical facilities required to
confirm these diagnoses is limited in developing countries in which
populations with a similar burden of disease exists. Clearly, the
benefits accrued by controlling the vertical transmission of HTLV-
1 in a resource poor setting must be considered relative to the
capacity of the health care system to ensure the safety of
alternative sources of infant nutrition. However, our data provides
strong support for public health interventions, such as improve-
ments to housing and community hygiene, that limit the exposure
of HTLV-1 carriers to other pathogens.
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